VITESSE: Epicutaneous Immunotherapy with DBV Peanut Patch in 4-7 year old Children.

Abstract

Peanut allergy is one of the most common causes of death and severe reactions from food allergies, an the number of children with a peanut allergy is increasing. Greenhawt and colleagues (2023), showed effectiveness and safety of epicutaneous peanut patch use in 362 toddlers, with epicutaneous immunotherapy for 12 months found superior to placebo in desensitizing children to peanuts and increasing the peanut dose that triggered allergic symptoms. Epworth is one of the few paediatric sites taking part in an international phase 3, double-blind, placebo-controlled, randomized study to assess the efficacy and safety of Epicutaneous Immunotherapy with DBV712 250 μg in 4-7-year-old children with peanut allergy.